17:33 EST TuHURA Biosciences (HURA) files $250M mixed securities shelf
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Plans Phase 2 Trial for TBS-2025
- TuHURA Biosciences Secures $3M Bridge Loan Agreement
- Tuhura Biosciences Advances in Merkel Cell Carcinoma Treatment Study
- Tuhura Biosciences’ Promising Phase 1 Trial: A Potential Game-Changer in Merkel Cell Carcinoma Treatment
- TuHURA Biosciences Extends Warrant Expiration to 2030